28 results about "Ketone concentration" patented technology

S-Beta-hydroxybutyric acid compositions for oral delivery are effective in rapidly raising blood ketone levels without causing acute acidosis or gastrointestinal (GI) distress when consumed in sufficiently dilute form and / or as a gel or suspension. By limiting added beta-hydroxybutyrate salts containing alkali or alkaline earth metal ions, beta-hydroxybutyric acid solutions, gels, or suspensions can deliver exogenous ketone bodies without significantly altering electrolyte balance. Although aqueous beta-hydroxybutyric acid solutions are moderately acidic with a pH of about 3.5 to 4, when diluted with sufficient water, the water acts as a pseudo buffering agent that offsets otherwise harsh acidic effects when consumed orally. Gels and suspensions can also ameliorate acidic effects by partially encapsulating the beta-hydroxybutyric acid. Beta-hydroxybutyric acid can be pure S-beta-hydroxybutyric acid or a non-racemic mixture enriched with S-beta-hydroxybutyric acid relative to R-beta-hydroxybutyric acid.

Compositions for delivering ketone bodies to a subject include one or more beta-hydroxybutyrate salts, one or more acetoacetate salts, beta-hydroxybutyric acid, and optionally acetoacetic acid. The compositions may optionally include one or more ketone body esters, such as one or more beta-hydroxybutyrate esters and / or one or more acetoacetate esters. An example composition contains about 2% to about 98% on a molar basis of the one or more beta-hydroxybutyrate salts and the one or more acetoacetate salts, about 2% to about 98% on a molar basis of the beta-hydroxybutyrate free acid and optionally the acetoacetate free acid, and optionally about 2% to about 98% on a molar basis of one or more ketone body esters.

This invention discloses a respiratory mask with multi-parameter detection capabilities, comprising: a main body of the respiratory mask and multiple sensors connected thereto; the multiple sensors include at least a carbon dioxide sensor, a pH sensor, and a ketone body sensor, used to detect the carbon dioxide concentration, pH value, and ketone body value in the patient's exhaled gas, respectively; the main body of the respiratory mask is provided with a one-way inlet valve and a one-way outlet valve, the one-way outlet valve being connected to one end of the outlet pipe to guide the exhaled gas to the outlet pipe; the carbon dioxide sensor and the ketone body sensor are both connected to one end of the outlet pipe; the main body of the respiratory mask is provided with a condensation structure to condense water vapor in the exhaled gas into condensate, and the condensate is transported to the pH sensor for detection through a condensate collection pipe. This invention can simultaneously detect multiple parameters, is simple and convenient to operate, and has high sensitivity, which helps to improve the accuracy of disease diagnosis.

An object of the present application is to provide a new composition for promoting ketogenesis. According to the present application, there is provided a composition for promoting ketogenesis containing one or two or more amino acids selected from the group consisting of citrulline, leucine, cysteine, taurine, glutamine and aspartic acid. The composition of the present application can further contain either or both of a medium-chain fatty acid and a medium-chain fatty acid ester.

The present disclosure provides a method for producing views related to data on glucose and ketone bodies and a related system. The method comprises receiving analyte data from an analyte sensor; determining, on the basis of the received analyte data, analyte concentration data comprising glucose concentration data and ketone body concentration data; and displaying, on the basis of the analyte concentration data, on a display unit a plurality of views comprising a first view, wherein the first view comprises a graphical display generated on the basis of the analyte concentration data over a time period, the graphical display comprises a region representing the distribution of a plurality of data points, and the position of each data point is determined by the glucose concentration and the ketone body concentration at the same time. The present disclosure enables an observer to more conveniently analyze energy metabolism and is friendlier to the observer.

The invention provides a compound which is a compound as shown in a formula I or a tautomer, a stereoisomer, a hydrate, a solvate, a pharmaceutically acceptable salt or a prodrug of the compound as shown in the formula I. OXCT1 protein can be effectively combined, and the dual-enzyme activity inhibition effect is achieved. Specifically, the compound not only can inhibit the activity of ketolytic enzyme of OXCT1, but also can inhibit the activity of succinyltransferase of OXCT1. Therefore, the compound can effectively prevent and / or treat cancers highly expressing OXCT1.

The invention provides a processing device based on analyte concentration data and a related method. The processing device comprises an acquisition module and a processing module, the acquisition module is used for receiving first analyte data related to glucose concentration and second analyte data related to ketone body concentration, wherein the first analyte data and the second analyte data are obtained by continuously monitoring at least two analytes of a target object through the analyte sensor. The processing module is configured to acquire analyte concentration data including glucose concentration data and ketone body concentration data based on the first analyte data and the second analyte data, acquire at least one feature set based on the analyte concentration data over a time period, and determine target information including at least energy information based on the at least one feature set, the energy information is the relationship between the estimated intake energy and consumed energy of the target object, the intake energy is the energy of the intake carbohydrate, and the consumed energy is the consumed energy. As a result, it is possible to improve the convenience of evaluating the relationship between intake and consumption of carbohydrates.

This application discloses an implantable dual-channel monitoring sensor and its fabrication method. The sensor includes a substrate and an electrode assembly, a sensing component, and a functional component disposed on the substrate. The sensing component includes a glucose sensing layer and a ketone body sensing layer, and the functional component includes a first functional film layer and a second functional film layer. The electrode assembly includes a first working electrode, a second working electrode, a reference electrode, and a counter electrode. The first working electrode has a glucose sensing layer disposed on it, and the second working electrode has a ketone body sensing layer disposed on it. The first functional film layer encapsulates the glucose sensing layer, and the second functional film layer encapsulates the ketone body sensing layer. This application enables dual-channel collaborative continuous monitoring and seamless integration of the two monitoring data. Furthermore, this implantable dual-channel monitoring sensor has low design cost, simple manufacturing process, and mass production advantages.

An organoleptically acceptable composition containing a ketone body or a ketone body precursor including a hydroxybutyrate ester and a flavouring is provided and gives improved palatability and user adherence to the intended dose regime. The flavouring may be a bitter flavouring and the composition may further contain an adsorbent for the ketone such that on ingestion, the bitterness of the composition may be masked. The composition may be in the form of a solid, gel or liquid and provides increased blood ketone levels and may be used in therapy or in treating muscle impairment or fatigue.

Systems, methods, and devices predict pharmacokinetic parameters following administration of a formulation, such as a medium-chain triglyceride (MCT). The method includes generating training data indicating human metabolism outcomes of the formulation. The training data includes stomach emptying parameters, a digestion rate, an absorption constant, or a conversion rate with a training target variable being ketone concentration or plasma free fatty acid concentration. The method also includes training a physiologically based biopharmaceutics (PBB) model with the training data and using the PBB model to predict, using the patient data, at least one of a target plasma free fatty acid concentration or a target ketone concentration. Furthermore, as part of a parameter sensitivity analysis of the PBB model, the method varies input parameters of the training data against a simulated mean plasma free fatty acid profile or a simulated mean ketone plasma profile.

The invention provides a compound which is a compound as shown in a formula I or a tautomer, a stereoisomer, a hydrate, a solvate, a pharmaceutically acceptable salt or a prodrug of the compound as shown in the formula I. The compound can be effectively combined with OXCT1 protein and exerts a dual enzyme activity inhibition effect. Specifically, the compound not only can inhibit the activity of ketolytic enzyme of OXCT1, but also can inhibit the activity of succinyltransferase of OXCT1. Therefore, the compound can effectively prevent and / or treat cancers highly expressing OXCT1.

The utility model belongs to the technical field of testing devices, and particularly relates to a device for testing the concentration of ketone in the milk of dairy cows in the perinatal period, which comprises a ketone body detector, and one surface of the ketone body detector is provided with an interface; a rectangular groove is formed in the side, close to the connector, of the ketone body detector, a rectangular block is slidably connected into the rectangular groove through a first spring, a connecting rod is fixedly installed on one side of the rectangular block, and a baffle is fixedly installed at the end, away from the rectangular block, of the connecting rod; through the designed structure, quick closing and protection are realized when the interface is not used, and the time of direct exposure of the interface is reduced, so that the situation that pollutants such as dust, impurities and water enter the interface to affect the accuracy of subsequent detection is reduced.

A method and composition for increasing or maintaining ketone body levels and improving metabolic functions, and use thereof. The method comprises administering to a subject in need thereof a composition comprising an effective amount of 3-acetoxybutyric acid or a pharmaceutically acceptable salt thereof, an ester thereof, or a derivative thereof. The composition further comprises an effective amount of 3-hydroxybutyric acid or a pharmaceutically acceptable salt thereof, an ester thereof, or a derivative thereof. Also provided is use of the composition in the preparation of a dietary supplement, food, beverage, or animal feed.

S-Beta-hydroxybutyric acid compositions for oral delivery are effective in rapidly raising blood ketone levels without causing acute acidosis or gastrointestinal (GI) distress when consumed in sufficiently dilute form and / or as a gel or suspension. By limiting added beta-hydroxybutyrate salts containing alkali or alkaline earth metal ions, beta-hydroxybutyric acid solutions, gels, or suspensions can deliver exogenous ketone bodies without significantly altering electrolyte balance. Although aqueous beta-hydroxybutyric acid solutions are moderately acidic with a pH of about 3.5 to 4, when diluted with sufficient water, the water acts as a pseudo buffering agent that offsets otherwise harsh acidic effects when consumed orally. Gels and suspensions can also ameliorate acidic effects by partially encapsulating the beta-hydroxybutyric acid. Beta-hydroxybutyric acid can be pure S-beta-hydroxybutyric acid or a non-racemic mixture enriched with S-beta-hydroxybutyric acid relative to R-beta-hydroxybutyric acid.

The purpose of the present disclosure is to provide a novel production method with which it is possible to produce a ketone body of diacetone glucose and diacetone allose in a relatively simple manner.　The present disclosure is a method for producing a solution containing a ketone body of diacetone glucose. The production method includes the following first to fourth steps.　The first step is a step for generating a first solution in which diacetone glucose is dissolved in an acetic acid ester.　The second step is a step in which a first aqueous solution containing an oxidizing agent is mixed with the first solution, and the diacetone glucose is oxidized into a ketone body thereof in the presence of an oxidation catalyst.　The third step is a step for separating a second solution after the oxidation reaction obtained in the second step into an organic solution and a second aqueous solution.　The fourth step is a step for obtaining the organic solution.

Disclosed herein are compositions that include a combination of: (1) a non-xanthine CNS stimulant or nootropic; (2) a ketone body or ketone body precursor, such as beta-hydroxybutyrate (BHB) salt, BHB ester, BHB acid, acetoacetate salt, acetoacetate ester, acetoacetic acid, 1,3-butanediol, medium chain fatty acid, or ester of medium chain fatty acid; and (3) optionally a dietetically or pharmaceutically acceptable carrier. The composition may include a vasodilator. The composition may include a short or medium chain fatty acid or ester thereof in addition to or instead of the ketone body or ketone body precursor. The composition can provide enhanced cognitive flexibility, improved sustained attention, improved working memory, and neuroprotection in a mammal. The composition can also beneficially increase resting energy expenditure (resting metabolic rate), particularly when in a state of ketosis, enhancing fat loss principally through ketosis while promoting muscle formation and maintenance, as well as modulating lethargy / lightheadedness when entering a ketogenic state.

Use of a ketone body and a ketone body ester for preserving glycogen and / or protein, thereby reducing muscle breakdown and improving endurance during exercise and promoting muscle recovery following exercise. Also for retarding muscle wasting in aging and disease. (R)-3-hydroxybutyl (R)-3-hydroxybutyrate for use in reducing muscle glycogen and protein breakdown during exercise or decreasing muscle wasting in aging and disease. Certain esters of hydroxybutyrate monomers, particularly a monoester of D-β-hydroxybutyrate with R-1,3-butanediol or with glycerol to reduce muscle breakdown and aid muscle recovery after exercise or retard muscle wasting. Compositions containing the ketone bodies or ketone body esters are also described.

The present disclosure provides esters and amides between known pharmaceutical, supplements, nutritional sugars, or nutritional compounds and ketone bodies and ketone body precursors with an enhanced bioavailability to mitigate adverse effects such as liver and kidney stress, gastrointestinal irritation, skin irritation, ulcers, and bleeding.

Systems are provided for an in vivo ketone sensor having a distal portion configured for placement in contact with an interstitial fluid of a user and a proximal portion including a working electrode, a sensing layer with β-hydroxybutyrate dehydrogenase, and a membrane layer configured to limit transport of one or more biomolecules. The in vivo ketone sensor is configured to generate signals at the working electrode corresponding to an amount of ketone in the interstitial fluid. Further, the systems includes a sensor control unit having at least one contact in electrical communication with the proximal portion of the sensor, which is configured to receive the generated signals, and convert the generated signals to ketone concentration data using a sensitivity associated with the in vivo ketone sensor. Also included is a transmitter configured to communicate ketone concentration data to a remote device.

To provide an oral supplement for ketogenic diet therapy that contains the components of a special milk containing medium-chain fatty acid oil and β-hydroxybutyric acid, which have been conventionally used as supplemental foods for enhancing blood ketone bodies in ketogenic diet therapy, and has an improved taste. [Solution] An oral composition containing 5-40% by mass of protein, 30-80% by mass of lipids, 0-15% by mass of carbohydrates, and 5-20% by mass of β-hydroxybutyric acid or its salt, wherein the ratio of medium-chain fatty acid oil in the lipids is 30% by mass or more.

A method of protecting animal tissue particularly skin, from damage caused by radiation exposure, by contacting the tissue with a ketone ester, a method of protecting skin, reducing the deterioration of skin or maintaining or improving the properties of skin by applying topically to the skin a ketone body comprising (R)-3-hydroxybutyrate moieties is disclosed. A ketone body comprising (R)-3-hydroxybutyrate moieties, especially enantiomerically enriched R-1,3-hydroxybutyl-(R)-3-hydroxybutyrate, for such uses is also provided.

Compositions and methods for administering ketone bodies to a subject include a ketone body or ketone body precursor complexed with or coupled to at least one amino acid. The compositions and methods cause one or more of: weight loss, weight maintenance, reduced blood glucose level, maintenance of blood glucose level, increased muscle and physical performance, enhanced metabolic and cellular repair, improved detoxification and gut health, targeted bioavailability, sustained release and controlled absorption, increased metabolic efficiency, enhanced cellular uptake, minimized side effects, multifunctional therapeutics, improved focus, improved energy, improved cognitive function, improved mental acuity, treatment of traumatic brain injury, treatment of diabetes, treatment of neurological disorder, treatment of cancer, treatment of inflammatory condition, appetite suppression, anti-aging effects, anti-glycation effects, treatment of epilepsy, treatment of depression, improved performance, improved muscle mass, improved motor function, increased strength, increased metabolism, increased fat loss, increased fat oxidation, improved body composition, and improved mood.

The invention belongs to the field of biological medicines, and provides an application of acetoacetic acid and derivatives thereof in preparation of medicines for treating or relieving hepatotoxicity caused by antituberculosis medicines. The hepatocytes formed by differentiation of human induced pluripotent stem cells are verified, and hydrazine is a metabolite with the strongest toxicity, so that the content of acetoacetic acid in the metabolite in the cells is reduced. Acetoacetic acid is one of main ketone metabolites in the ketone metabolism process, and cells can convert acetoacetic acid into acetoacetyl coenzyme A through succinyl coenzyme A: 3-oxo acid coenzyme A transferase. According to the invention, the OXCT1 gene in the human induced pluripotent stem cell is knocked out through CRISPR-cas9 and the human induced pluripotent stem cell is differentiated into the hepatocyte, so that the knockout of the OXCT1 gene increases the content of acetoacetic acid and reduces hepatic differentiation cell death caused by hydrazine.

Provided in the present disclosure are an analyte concentration data-based processing device and a related method. The processing device comprises an acquisition module and a processing module. The acquisition module is configured to receive first analyte data related to a glucose concentration and second analyte data related to a ketone body concentration obtained by continuously monitoring at least two analytes of a target subject using an analyte sensor. The processing module is configured to acquire, on the basis of the first analyte data and the second analyte data, analyte concentration data comprising glucose concentration data and ketone body concentration data, acquire, on the basis of the analyte concentration data within a time period, at least one feature set, and determine, on the basis of the at least one feature set, target information at least comprising energy information. The energy information is the relationship between estimated energy intake and energy expenditure of the target subject, where the energy intake is the energy derived from ingested carbohydrates, and the energy expenditure is the energy that is consumed. Therefore, the convenience of evaluating the relationship between carbohydrate intake and consumption can be improved.

The present disclosure provides a method of generating a view related to data of glucose and ketone bodies, and a related system. The method includes receiving analyte data from an analyte sensor; determining analyte concentration data including glucose concentration data and ketone body concentration data based on the received analyte data; and displaying a plurality of views including a first view on a display unit based on the analyte concentration data, the first view including a graphical display generated based on the analyte concentration data over a time period, the graphical display including a region representing a distribution of the plurality of data points, the position of each data point is determined by the glucose concentration and the ketone body concentration at the same time. According to the invention, the convenience of analyzing the energy metabolism condition by an observer can be improved, and the method is more friendly to the observer.

The present invention relates to non-invasive methods of diagnosing primary aldosteronism (PA), preferably in subjects in need of such diagnosis. As described herein, it was discovered that the concentration of plasma parathyroid hormone (PTH) in blood samples isolated from subjects was predictive of a diagnosis of primary aldosteronism depending on the plasma aldosterone concentration (PAC), plasma renin concentration (PRC), and plasma renin activity (PRA). Preferably PAC, PRC, and PRA are measured from the same blood sample as the concentration of plasma parathyroid hormone.

The invention discloses a ketone body biosensor and a preparation method thereof.The ketone body biosensor comprises a substrate, a working electrode, a reference electrode, a counter electrode, an active enzyme layer and an outer membrane adjusting layer, the working electrode and the reference electrode are distributed on one face of the substrate, the counter electrode is distributed on the other opposite face of the substrate, the active enzyme layer is arranged on the surface of the working electrode, and the outer membrane adjusting layer is arranged on the surface of the working electrode. And the working electrode, the reference electrode and the counter electrode are completely wrapped by the outer membrane adjusting layer. The ketone body biosensor provided by the invention is stable in performance, safe, reliable and high in sensitivity, can continuously monitor the change of the beta-hydroxybutyric acid level in the body, is stable and mature in preparation process, and is beneficial to improving the production efficiency.

A ketogenic R-beta-hydroxybutyrate mixed salt-acid composition includes enantiomerically pure R-beta-hydroxybutyric acid and one or more enantiomerically pure R-beta-hydroxybutyrate salts. The R-beta-hydroxybutyric acid is more rapidly absorbed and utilized by the body than salts or esters, enhances taste, and reduces the need to include citric acid or other edible acids. The enantiomerically pure R-beta-hydroxybutyrate salt(s) are more slowly absorbed and utilized by the body and can provide one or more electrolytes. Compositions for increasing ketone body level in a subject may contain a dietetically or pharmaceutically acceptable carrier and an R-beta-hydroxybutyrate mixed salt-acid composition. The composition contains less than 100% by molar equivalents of total enantiomerically pure R-beta-hydroxybutyrate salts and more than 0% by molar equivalents of enantiomerically pure R-beta-hydroxybutyric acid.